CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
CASI Pharmaceuticals, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$0.10+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | During market hours | $6.90M | – | – |
Press releases
Announcements CASI Pharmaceuticals filed with the SEC
Half 2026 Business and Financial Results
EX-99.1 to Form 6-K
Receives the Delisting Decision from the Nasdaq Hearings Panel
EX-99.1 to Form 6-K
Receives Extension from Nasdaq to Meet Listing Requirements
EX-99.1 to Form 6-K
Announces Up to $20 Million Convertible Note Financing
EX-99.1 to Form 6-K
Pharmaceuticals Announces Changes in Board Governance
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Receives and Appeals Delisting Determination from NASDAQ
EX-99.1 to Form 6-K
Appoints James Huang to Board of Directors
EX-99.1 to Form 6-K
Appoints Barbara Krebs-Pohl, PhD to Board of Directors
EX-99.1 to Form 6-K
South San Francisco, California / August 29, 2025 / ACCESS
EX-99.1 to Form 6-K
Announces FDA Clearance of IND Application for CID-103 in Renal
EX-99.1 to Form 6-K
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer
EX-99.1 to Form 6-K
CASI PHARMACEUTICALS PROVIDES BUSINESS AND CLINICAL
EX-99.1 to Form 6-K
CASI Pharmaceuticals Inc. 1 Business and Clinical Update May 21, 2025
EX-99.2 to Form 6-K
FIRST QUARTER 2025 BUSINESS AND FINANCIAL RESULTS
EX-99.1 to Form 6-K
PHARMACEUTICALS ENTERS INTO DEFINITIVE AGREEMENT
EX-99.1 to Form 6-K
CASI PHARMACEUTICALS RECEIVES NASDAQ DEFICIENCY
EX-99.1 to Form 6-K
RECEIPT OF AN UPDATED NON-BINDING PROPOSAL TO
EX-99.1 to Form 6-K
FOURTH QUARTER AND FULL-YEAR 2024 BUSINESS AND
EX-99.1 to Form 6-K
THIRD QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
EX-99.1 to Form 6-K
SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
EX-99.1 to Form 6-K
FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
EX-99 to Form 6-K
FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
EX-99 to Form 6-K
QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
EX-99.1 to Form 6-K
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL
EX-99.1 to Form 6-K
SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
EX-99.1 to Form 6-K
CASI Pharmaceuticals Acquires Global Intellectual
EX-99.1 to Form 6-K
FIRST QUARTER 2023 FINANCIAL RESULTS
EX-99.1 to Form 6-K
FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL
EX-99.1 to Form 6-K
BEIJING, China (March 21, 2023) CASI Pharmaceuticals,
EX-99.1 to Form 6-K